PRN1008 is a reversible covalent inhibitor of Bruton’s tyrosine kinase (BTK), developed to modulate B-cell signaling and immune responses in the treatment of conditions such as immune thrombocytopenia… Read more
PRN1008 is a reversible covalent inhibitor of Bruton’s tyrosine kinase (BTK), developed to modulate B-cell signaling and immune responses in the treatment of conditions such as immune thrombocytopenia and pemphigus vulgaris. As a critical pharmaceutical reference standard, this compound and its associated forms are essential for laboratories engaged in drug development and rigorous quality control. The category includes both the parent drug and stable isotope labelled compounds, such as the deuterated analogue PRN1008-d5, which act as vital internal standards for mass spectrometry-based bioanalysis. These high-quality materials enable researchers to conduct precise impurity profiling, validate analytical methods, and ensure the consistent characterization of drug substances throughout the synthesis and development lifecycle. By utilizing these reference standards, analytical chemists can accurately quantify drug levels in complex biological matrices and maintain strict compliance with regulatory standards for drug safety and efficacy.